7-chloro-thieno[2,3-c]pyridine-2-sulfonyl chloride | 259821-52-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 7-chloro-thieno[2,3-c]pyridine-2-sulfonyl chloride
• 英文别名: 7-Chlorothieno[2,3-c]pyridine-2-sulfonic acid chloride；7-chlorothieno[2,3-c]pyridine-2-sulfonyl chloride
• CAS: 259821-52-8
• 化学式: C₇H₃Cl₂NO₂S₂
• 分子量: 268.144
• InChiKey: PZESPDGIXVFVKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-chloro-thieno[2,3-c]pyridine-2-sulfonyl chloride 、 2-(3-(S)-Amino-2-oxo-pyrrolidin-1-ylmethyl)-pyrrolo[3,2-b]pyridine-1-carboxylic acid tert-butyl ester 生成 7-Chloro-thieno[2,3-c]pyridine-2-sulfonic acid [(S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-pyrrolidin-3-yl]-amide
  参考文献：
  名称：

  Solid-phase parallel synthesis of azarene pyrrolidinones as factor Xa inhibitors

  摘要：

  A focused library (4 x 14) prepared from 4-aminopyridine and 4-, 5-, and 6-azoindole templates was synthesized using 14 polymer supported 4-amido-2,3,5,6-tetrafluorophenyl (TFP) sulfonate esters inputs. Several compounds were identified as factor Xa inhibitors (IC(50)less than or equal to 0.1 mu M) helping to establish the SAR among these four series of azarene pyrrolidinones. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00151-7

文献信息

• Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors
  作者：Michael R. Becker、William R. Ewing、Roderick S. Davis、Henry W. Pauls、Cuong Ly、Aiwen Li、Helen J. Mason、Yong Mi Choi-Sledeski、Alfred P. Spada、Valeria Chu、Karen D. Brown、Dennis J. Colussi、Robert J. Leadley、Ross Bentley、Jeff Bostwick、Charles Kasiewski、Suzanne Morgan

  DOI：10.1016/s0960-894x(99)00466-7

  日期：1999.9

  Thienopyridine sulfonamide pyrrolidinones were found to be potent and selective inhibitors of the coagulation cascade enzyme factor Xa. SAR studies led to several compounds that were selected for further in vivo investigation. These novel aryl binding pocket moieties represent a structural modification to a series of fXa inhibitors. Several compounds proved to be efficacious i.v. antithrombotic agents

  发现噻吩并吡啶磺酰胺吡咯烷酮是凝血级联酶因子Xa的有效和选择性抑制剂。SAR研究导致选择了几种化合物进行进一步的体内研究。这些新颖的芳基结合口袋部分代表了一系列fXa抑制剂的结构修饰。几种化合物被证明是有效的静脉抗血栓药。
• SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS
  申请人：RHONE-POULENC RORER PHARMACEUTICALS, INC.

  公开号：EP0894088A1

  公开（公告）日：1999-02-03
• EP0894088A4
  申请人：——

  公开号：EP0894088A4

  公开（公告）日：2001-12-05
• US6034093A
  申请人：——

  公开号：US6034093A

  公开（公告）日：2000-03-07
• [EN] SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS<br/>[FR] COMPOSES SUBSTITUES A BASE DE N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE ACIDE SULFONIQUE
  申请人：——

  公开号：WO1998024784A1

  公开（公告）日：1998-06-11

  [EN] The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
  [FR] La présente invention concerne des composés représentés par la formule générale (I) et dont l'activité pharmaceutique dont ils font preuve les désigne particulièrement pour une incorporation dans des compositions pharmaceutiques destinées au traitement de patients souffrant de certains troubles médicaux. L'activité de ces composés est principalement une activité inhibitrice du facteur Xa. L'invention concerne ainsi, non seulement des composés représentés par la formule générale (I), des compositions contenant des composés de représentés par la formule générale (I), mais également leur utilisation pour traiter des patients atteints de troubles pathologiques s'atténuant avec l'administration d'un inhibiteur de l'activité du facteur Xa.